Model-Informed Dose Optimization of Pazopanib in Real-World Patients with Cancer
These findings suggest that an initial pazopanib dose of 600 mg fasted, followed by model-informed precision dosing to maintain C<sub>min,ss</sub> between 20 and 34 mg/L, may improve efficacy-toxicity balance and mitigate treatment interruptions.
Authors
- Amy Rieborn (ORCID: https://orcid.org/0000-0002-8515-7538)
- Hans A. J. Gelderblom (ORCID: https://orcid.org/0000-0001-9270-8636)
- Anyue Yin (ORCID: https://orcid.org/0000-0001-9924-6040)
- Catherijne A. J. Knibbe (ORCID: https://orcid.org/0000-0001-9893-4415)
- Dirk Jan A. R. Moes (ORCID: https://orcid.org/0000-0003-3219-253X)
- Zhiyuan Tan (ORCID: https://orcid.org/0000-0003-2681-6932)
- Swantje Völler (ORCID: https://orcid.org/0000-0003-0587-2775)
- Tom van der Hulle (ORCID: https://orcid.org/0000-0002-2296-1828)
Institutions
- Leiden University (NL)
- Leiden University Medical Center (NL)
- St. Antonius Ziekenhuis (NL)
- Centre for Human Drug Research (NL)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1007/s40262-025-01504-5
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04